SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announces that the last patient has completed the last single-dose
cohort of the SBE-01 clinical study. This marks the end of the first part (SAD*
phase 1a) of SBE-01 (EudraCT no. 2021-000314-42).

The Safety Monitoring Committee (SMC) has now recommended the study to continue
to enter the last phase (MAD** phase 1b) based on encouraging safety and
antimicrobial effect measures. In this part of the SBE-01 study we will test the
recommended SBE-product once or multiple times daily over 5 days. This will
further document the safety, tolerability, and antimicrobial efficacy when SBE
is administered on a more intense and clinically relevant treatment schedule.
The phase 1b will establish a tolerable dose and treatment schedule for SBE to
be able to develop it into an effective infection-treatment solution in
problematic, non-healing wounds.

SBE-01 is the first-in-human (phase 1) study with the SoftOx's lead wound care
product, SBE (SoftOx Biofilm Eradicator), designed to treat infected chronic
wounds. Chronic wounds represent a silent epidemic with an estimated 40 million
chronic wounds worldwide and two million related amputations annually. As these
wounds last on average 12/13 months and recur in up to 70% of patients, they can
lead to loss of function and decreased quality of life as well as are a
significant cause of morbidity. SoftOx is currently exploring different
indications such as venous leg ulcers and diabetic foot ulcers with the aim to
improve the treatment and quality of life for these patients. 

* SAD: single ascending dose, **MAD: Multiple ascending dose

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, CMO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
biotech/medtech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com.